• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
【24h】

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

机译：艾司西酞普兰预防广泛性社交焦虑症的24周随机，双盲，安慰剂对照研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Escitalopram has proven efficacy in the short-term treatment of generalized social anxiety disorder (SAD). The present relapse prevention study investigated relapse rates during a 24-week, randomized, double-blind, placebo-controlled period in patients with generalized SAD who had responded to 12-week open-label treatment with escitalopram. METHOD: A total of 517 patients with a primary diagnosis of generalized SAD (per DSM-IV criteria) and a Liebowitz Social Anxiety Scale (LSAS) total score of >/= 70 received 12 weeks of open-label treatment with flexible doses (10-20 mg/day) of escitalopram. Of these patients, 371 responded (Clinical Global Impressions-Improvement scale [CGI-I] score of 1 or 2) and were randomly assigned to 24 weeks of double-blind treatment with escitalo-pram (10 or 20 mg/day) (N = 190) or placebo (N = 181), continuing with the dose level administered at the end of the open-label period. Relapse was defined as either an increase in LSAS total score of >/= 10 or withdrawaldue to lack of efficacy, as judged by the investigator. The study was conducted from January 2001 to June 2002. RESULTS: Survival analysis of relapse and time to relapse showed a significant advantage for escitalopram compared to placebo (log-rank test: p < .001). The risk of relapse was 2.8 times higher for placebo-treated patients than for escitalopram-treated patients (p < .001), resulting in significantly fewer escitalopram-treated patients relapsing (22% vs. 50%), at both doses. Escitalopram was well tolerated during double-blind treatment of generalized SAD, and only 2.6% of the escitalopram-treated patients withdrew because of adverse events. The overall discontinuation rate, excluding relapses, was 13.2% for patients treated with escitalopram and 8.3% for patients treated with placebo. CONCLUSION: Escitalopram was effective and well tolerated in the long-term treatment of generalized SAD.
机译：目的：艾司西酞普兰在短期治疗广义社交焦虑症（SAD）中已证明具有疗效。目前的复发预防研究调查了对12周开放式依他普仑治疗有反应的广义SAD患者在24周，随机，双盲，安慰剂对照期间的复发率。方法：共有517例初步诊断为广义SAD（根据DSM-IV标准）且利勃维茨社交焦虑量表（LSAS）总得分> / = 70的患者接受了为期12周的灵活剂量的开放标签治疗（10 -20 mg / day）依他普仑。在这些患者中，有371例反应良好（临床总体印象-改善量表[CGI-I]评分为1或2），并被随机分配为使用艾司他洛-普仑（10或20 mg /天）的双盲治疗24周（N = 190）或安慰剂（N = 181），并在开放标签期结束时继续服用剂量水平。根据研究者的判断，复发定义为LSAS总分增加> / = 10或由于缺乏疗效而退出。该研究于2001年1月至2002年6月进行。结果：与安慰剂相比，依他普仑对复发和复发时间的生存分析显示出显着优势（对数秩检验：p <.001）。两种剂量的安慰剂治疗患者的复发风险比依他普仑治疗的患者高2.8倍（p <.001），从而导致依他普仑治疗的患者复发的几率明显降低（22％vs. 50％）。在广义SAD的双盲治疗期间，依西酞普兰的耐受性良好，只有2.6％依西酞普兰治疗的患者因不良事件而退出治疗。依他普仑治疗的总停药率（不包括复发）为13.2％，安慰剂治疗的为8.3％。结论：艾司西酞普兰在广义SAD的长期治疗中有效且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号